These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8723475)

  • 1. In vitro activity of the tricyclic beta-lactam GV104326.
    Wise R; Andrews JM; Brenwald N
    Antimicrob Agents Chemother; 1996 May; 40(5):1248-53. PubMed ID: 8723475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of sanfetrinem (GV104326), a new trinem antimicrobial agent, versus Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Doern GV; Pierce G; Brueggemann AB
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):39-42. PubMed ID: 8950528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria.
    Di Modugno E; Erbetti I; Ferrari L; Galassi G; Hammond SM; Xerri L
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2362-8. PubMed ID: 7840571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
    Davies TA; Kelly LM; Hoellman DB; Ednie LM; Clark CL; Bajaksouzian S; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Critchley IA; Karlowsky JA; Draghi DC; Jones ME; Thornsberry C; Murfitt K; Sahm DF
    Antimicrob Agents Chemother; 2002 Feb; 46(2):550-5. PubMed ID: 11796376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
    Fenoll A; Aguilar L; Robledo O; Giménez MJ; Tarragó D; Granizo JJ; Gimeno M; Coronel P
    J Antimicrob Chemother; 2007 Aug; 60(2):323-7. PubMed ID: 17562681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of BAY v 3522, a new oral cephalosporin.
    Fass RJ
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1855-7. PubMed ID: 2126697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
    Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
    Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.
    Jacobs MR; Bajaksouzian S; Zilles A; Lin G; Pankuch GA; Appelbaum PC
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1901-8. PubMed ID: 10428910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM; Suter M; Borsos S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem.
    Di Modugno E; Broggio R; Erbetti I; Lowther J
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2742-8. PubMed ID: 9420050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.
    Thornsberry C; Ogilvie P; Kahn J; Mauriz Y
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):249-57. PubMed ID: 9458982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
    Pontani D; Washton H; Bouchillon S; Johnson J
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.
    Souli M; Wennersten CB; Eliopoulos GM
    Int J Antimicrob Agents; 1998 Apr; 10(1):23-30. PubMed ID: 9624540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serotype distribution and drug resistance of
    Tian HL; Shi W; Zhou HF; Yuan L; Yao KH; Rexiati D; Xu AM
    Zhonghua Er Ke Za Zhi; 2018 Apr; 56(4):279-283. PubMed ID: 29614568
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.